Printer Friendly

OncoSec Medical doses first patient in TRIFECTA.

M2 EQUITYBITES-May 27, 2019-OncoSec Medical doses first patient in TRIFECTA

(C)2019 M2 COMMUNICATIONS http://www.m2.com

It was reported on Friday that OncoSec Medical, a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, has dosed its first patient in its TRIFECTA triple combination clinical trial of OncoSec's TAVO, an IDO1 drug (epacadostat) and KEYTRUDA in patients with unresectable squamous cell carcinoma head and neck cancer.

Dr Chase Heaton, MD, an oncologic head and neck surgeon at UCSF, led the study in collaboration with Dr Alain Algazi, leader of the Head and Neck Medical Oncology Program at UCSF and Clinical Strategic Advisor to OncoSec. Preliminary data from the TRIFECTA study is expected later this year.

The triple combination of IL-12, IDO1 and anti-PD-1 monoclonal antibody is a first-of-its-kind clinical trial and aims to assess this three-way combination in squamous cell carcinoma head and neck cancer and to potentially expand testing to other tumour types if successful.

TRIFECTA is an investigator-initiated, single-arm, open-label clinical trial in which 35 evaluable unresectable squamous cell carcinoma head and neck cancer patients will receive TAVO, pembrolizumab, and epacadostat.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 27, 2019
Words:195
Previous Article:Wellesley Bancorp names board director.
Next Article:China's National Medical Products Administration approves GlaxoSmithKline's Shingrix vaccine.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters